Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/AbbVie Move Beyond GDC-0199 Toxicity Issue To Show Results In Tough-To-Treat CLL

This article was originally published in The Pink Sheet Daily

Executive Summary

Small molecule Bcl-2 inhibitor GDC-0199/ABT-199 demonstrates an 84% overall response rate and a 23% complete response in early study of high risk CLL presented at ASH. However, tumor lysis syndrome caused one sudden death in the trial and is a potential risk that needs to be well-managed going forward. Roche also reports updated results of Gazyva vs. Rituxan in CLL.

Advertisement

Related Content

FDA Accentuates Venclexta Superiority To Imbruvica
Venclexta Out Of The Starting Gate With Approval In High-Risk CLL Subset
Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel